Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel - pretreated ovarian carcinoma

Gynecologic Oncology

Volumn 118, Issue 1, 2010, Pages 52-57

  Pectasides, D ^a   Pectasides, E ^a   Papaxoinis, G ^a   Psyrri, A ^a   Pliarchopoulou, K ^a   Koumarianou, A ^a   Macheras, A ^a   Athanasas, G ^a   Xiros, N ^a   Economopoulos, T ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Alternating chemotherapy; Carboplatin; Cyclophosphamide; Gemcitabine; Pegylated liposomal doxorubicin; Platinum refractory resistant ovarian cancer

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; CA 125 ANTIGEN; CARBOPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG TOXICITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEROLOGY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 77953478466     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.03.003     Document Type: Article

References (31)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., and Thun M.J. CA Cancer J Clin 59 (2009) 225-249
2. Markman M., and Bookman M.A. Second-line treatment of ovarian cancer. Oncologist 5 (2000) 26-35
3. Papadimitriou C.A., Fountzilas G., Aravantinos G., et al. Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study. Gynecol Oncol 92 (2004) 152-159
4. Pfisterer J., Plante M., Vergote I., et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24 (2006) 4699-4707
5. Markman M. Second-line therapy for potentially platinum-sensitive recurrent ovarian cancer: what is optimal treatment?. Gynecol Oncol 81 (2001) 1-2
6. Bookman M.A. Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic. Int J Gynecol Cancer 15 Suppl 1 (2005) 12-17
7. Muggia F.M., Hainsworth J.D., Jeffers S., et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15 (1997) 987-993
8. Gordon A.N., Granai C.O., Rose P.G., et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 18 (2000) 3093-3100
9. Mutch D., Orlando M., Teneriello T., et al. Randomized phase III trial of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLDOX) for patients (pts) with platinum-resistant (pt-r) ovarian cancer (oc) undergoing second or third-line chemotherapy (ct). Eur J Cancer Suppl 3 (2005) 262
10. Peters G.J., Van Moorsel C.J., Lakerveld B., et al. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines. Int J Oncol 28 (2006) 237-244
11. Tewari D., Monk B.J., Hunter M., Falkner C.A., and Burger R.A. Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma. Invest New Drugs 22 (2004) 475-480
12. Brewer C.A., Blessing J.A., Nagourney R.A., Morgan M., and Hanjani P. Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 103 (2006) 446-450
13. Kavanagh J., Tresukosol D., Edwards C., et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 13 (1995) 1584-1588
14. Bozas G., Bamias A., Koutsoukou V., et al. Biweekly gemcitabine and cisplatin in platinum-resistant/ refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma. Gynecol Oncol 104 (2007) 580-585
15. Ferrero J.M., Weber B., Geay J.F., et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 18 (2007) 263-268
16. Rapoport B.L., Vorobiof D.A., Slabber C C., et al. Phase II study of liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer. Int J Gynecol Cancer 19 (2009) 1137-1141
17. Power P., Stuart G., Oza A., et al. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study. Gynecol Oncol 114 (2009) 410-414
18. Lawton F., Meanwell C., Mould J., and Blackledge G. A five-drug alternating chemotherapy regimen for patients with advanced epithelial ovarian cancer. Gynecol Oncol 36 (1990) 19-22
19. Pectasides D., Xiros N., Papaxoinis G., et al. Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma. Gynecol Oncol 108 (2008) 47-52
20. Zoli W., Ricotti L., Barzanti F., et al. Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines. Int J Cancer 80 (1999) 413-416
21. Guppy A.E., and Rustin G.J. CA125 response: can it replace the traditional response criteria in ovarian cancer. Oncologist 7 (2002) 437-443
22. Rustin G.J., Quinn M., Thigpen T., et al. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 92 (2000) 205-216
23. World Health Organization. WHO handbook for reporting results of cancer treatment. WHO Offset Publication vol. 48, Switzerland (1979), World Health Organization, Geneva
24. Leitao Jr. M.M., Hummer A., Dizon D.S., Aghajanian C., Hensley M., and Sabbatini P. Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecol Oncol 91 (2003) 123-129
25. du Bois A., Pfisterer J., Burchardi N., et al. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). Gynecol Oncol 107 (2007) 518-525
26. Alberts D.S., Liu P.Y., Wilczynski S.P., et al. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol Oncol 108 (2008) 90-94
27. Pujade-Lauraine E., Mahner S., Kaern J., et al. A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG). J Clin Oncol 27 18 Suppl (2009) 799s [abstract LBA5509]
28. Bafaloukos D., Linardou H., Aravantinos G., et al. A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study. BMC Med 8 (2010) 3
29. D'Agostino G., Ferrandina G., Ludovisi M., et al. Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. Br J Cancer 89 (2003) 1180-1184
30. Skarlos D.V., Kalofonos H.P., Fountzilas G., et al. Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study. Anticancer Res 25 (2005) 3103-3108
31. Valerio M.R., Tagliaferri P., Raspagliesi F., et al. A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma. Int J Gynecol Cancer 16 Suppl 1 (2006) 79-85